CS32582, a highly selective small molecule allosteric inhibitor of tyrosine kinase 2 (TYK2), is exclusively discovered by the company with global patent protection and achieves selective inhibition of TYK2 by specifically binding to the regulatory pseudokinase JH2 domain of TYK2, and it does not inhibit the kinases JAK1, JAK2, and JAK3 of the same family at therapeutic doses, thereby exerting therapeutic effects while bringing good safety. The inhibition of CS32582 on TYK2 effectively blocks the downstream signaling pathways mediated by cytokines such as interleukin (IL)-23, IL-12, and type I interferon (IFN), thereby exerting therapeutic effects on autoimmune diseases such as psoriasis.

Indications under development

• In Dec. 2024, a phase 1 clinical trial of CS32582 had been completed, and the company was preparing the protocol design for a phase 2 clinical trial in patients with psoriasis.